{"hands_on_practices": [{"introduction": "Before we can interpret an assay for Heparin-Induced Thrombocytopenia (HIT), we must understand what it detects. This practice delves into the core physicochemical principles of HIT, exploring how the stoichiometry of Platelet Factor 4 (PF4) and heparin is crucial for forming the antigenic complexes that HIT antibodies recognize [@problem_id:5224041]. By calculating the optimal molar ratio based on charge neutrality, you will gain insight into why assay design and reagent concentrations are critical for achieving maximum sensitivity.", "problem": "A core feature of the immunoassays used in laboratory diagnostics for Heparin-Induced Thrombocytopenia (HIT) is the dependence of antigenicity on the stoichiometry of complexes formed between Platelet Factor 4 (PF4) and heparin. Antigenicity peaks when the PF4–heparin complexes approach electrostatic charge neutrality, a well-tested observation for polyelectrolyte complexes. Consider an enzyme-linked immunosorbent assay (ELISA) that detects immunoglobulin binding to PF4–heparin complexes. Assume PF4 is predominantly tetrameric under the assay conditions, and model antigenicity as maximized near the PF4 tetramer to single heparin chain ratio that achieves charge neutrality.\n\nYou are provided the following scientifically plausible parameters and assay setup:\n- PF4 monomer molecular weight $M_{\\text{PF4,mono}} = 7.8 \\times 10^{3} \\,\\mathrm{g/mol}$; PF4 is predominantly tetrameric (fraction $\\phi \\approx 1$).\n- Net charge per PF4 tetramer $z_{t} = +12$ at physiological pH.\n- Heparin chain average molecular weight $M_{\\text{hep}} = 1.5 \\times 10^{4} \\,\\mathrm{g/mol}$.\n- Average number of disaccharides per heparin chain $L = 40$.\n- Net charge per disaccharide $z_{d} = -2$; hence total negative charge per chain is $z_{-} = L \\, |z_{d}|$.\n- Heparin potency $P = 180 \\,\\mathrm{IU/mg}$.\n- Assay PF4 monomer concentration $C_{\\text{PF4,mono}} = 1.2 \\times 10^{-6} \\,\\mathrm{mol/L}$.\n- Heparin dose in the assay well $H = 0.5 \\,\\mathrm{IU/mL}$.\n\nUsing charge neutrality as the fundamental base (antigenicity is maximized when the net charge of the PF4–heparin complex is approximately zero), do the following:\n1. Derive the expression for the optimal molar ratio $r^{\\ast}$ of PF4 tetramers per single heparin chain that maximizes antigenicity, in terms of $z_{t}$ and $z_{-}$.\n2. Evaluate $r^{\\ast}$ numerically using the provided values. Round your answer to $4$ significant figures. Express the ratio as a dimensionless quantity (PF4 tetramers per heparin chain).\n3. Using $C_{\\text{PF4,mono}}$, $H$, $P$, and $M_{\\text{hep}}$, compute the actual PF4 tetramer to heparin chain ratio $r_{\\text{mix}}$ present in the described assay mixture. Treat all PF4 as tetrameric and assume one heparin chain per polymer molecule. Determine whether $r_{\\text{mix}}$ falls within a high-antigenicity window defined by $|Q| \\le \\alpha \\, z_{-}$ with $\\alpha = 0.1$, where $Q$ is the residual net charge of a complex composed of one heparin chain and $r$ PF4 tetramers.\n4. Explain, from first principles of polyelectrolyte complex formation and mass action, how deviations from $r^{\\ast}$ reduce immunoassay signal intensity.\n\nOnly report the single optimal ratio $r^{\\ast}$ in your final numeric answer, rounded to $4$ significant figures and with no units.", "solution": "The problem is first subjected to validation.\n\n### Step 1: Extract Givens\n- PF4 monomer molecular weight: $M_{\\text{PF4,mono}} = 7.8 \\times 10^{3} \\,\\mathrm{g/mol}$\n- PF4 tetrameric fraction: $\\phi \\approx 1$\n- Net charge per PF4 tetramer: $z_{t} = +12$\n- Heparin chain average molecular weight: $M_{\\text{hep}} = 1.5 \\times 10^{4} \\,\\mathrm{g/mol}$\n- Average number of disaccharides per heparin chain: $L = 40$\n- Net charge per disaccharide: $z_{d} = -2$\n- Total negative charge per heparin chain: $z_{-} = L \\, |z_{d}|$\n- Heparin potency: $P = 180 \\,\\mathrm{IU/mg}$\n- Assay PF4 monomer concentration: $C_{\\text{PF4,mono}} = 1.2 \\times 10^{-6} \\,\\mathrm{mol/L}$\n- Heparin dose in assay well: $H = 0.5 \\,\\mathrm{IU/mL}$\n- High-antigenicity window condition: $|Q| \\le \\alpha \\, z_{-}$ with $\\alpha = 0.1$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in the principles of polyelectrolyte complex formation, which is the accepted physicochemical basis for the generation of antigenic complexes in Heparin-Induced Thrombocytopenia (HIT). The parameters provided (molecular weights, charges, concentrations) are realistic for the biomolecules and assay conditions described. The problem is well-posed, stating a clear objective (calculate the optimal ratio $r^{\\ast}$) based on a physically meaningful criterion (charge neutrality). The language is objective and the data are internally consistent and sufficient to perform all required calculations. No scientific laws are violated, and no information is missing or contradictory. The problem does not exhibit any of the flaws listed in the validation criteria.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A full solution will be provided.\n\n### Solution\nThe solution is structured to address the four parts of the problem statement.\n\n**1. Derivation of the expression for the optimal molar ratio $r^{\\ast}$**\n\nThe core assumption is that antigenicity is maximized when the PF4–heparin complex is electrostatically neutral. Let $r$ be the molar ratio of PF4 tetramers to heparin chains in a complex. A single complex is thus composed of $r$ PF4 tetramers and one heparin chain.\n\nThe total positive charge contributed by the PF4 tetramers is $r \\times z_{t}$.\nThe total negative charge contributed by one heparin chain is $-z_{-}$. Note that $z_{-}$ is defined as the magnitude of the total negative charge, $z_{-} = L \\, |z_{d}|$, so it is a positive value.\n\nFor charge neutrality, the net charge $Q$ of the complex must be zero.\n$$Q = r \\cdot z_{t} - z_{-} = 0$$\nThe optimal ratio, $r^{\\ast}$, is the value of $r$ that satisfies this equation. Solving for $r^{\\ast}$:\n$$r^{\\ast} \\cdot z_{t} = z_{-}$$\n$$r^{\\ast} = \\frac{z_{-}}{z_{t}}$$\nSubstituting the definition of $z_{-}$:\n$$r^{\\ast} = \\frac{L \\, |z_{d}|}{z_{t}}$$\nThis expression represents the optimal molar ratio of PF4 tetramers to heparin chains for maximum antigenicity based on charge neutrality.\n\n**2. Numerical evaluation of $r^{\\ast}$**\n\nWe use the provided values: $L = 40$, $z_{d} = -2$ (so $|z_{d}| = 2$), and $z_{t} = 12$.\n\nFirst, we calculate the magnitude of the total charge on a heparin chain, $z_{-}$:\n$$z_{-} = L \\, |z_{d}| = 40 \\times 2 = 80$$\nNow, we can calculate the optimal ratio $r^{\\ast}$:\n$$r^{\\ast} = \\frac{z_{-}}{z_{t}} = \\frac{80}{12} = \\frac{20}{3} \\approx 6.6666...$$\nRounding to $4$ significant figures as requested:\n$$r^{\\ast} \\approx 6.667$$\nThis means that peak antigenicity is expected when approximately $6.667$ PF4 tetramers are complexed with a single heparin chain.\n\n**3. Calculation of the actual ratio $r_{\\text{mix}}$ and antigenicity check**\n\nWe need to determine the molar concentrations of PF4 tetramers ($C_{\\text{PF4,tetra}}$) and heparin ($C_{\\text{hep}}$) in the assay mixture.\n\nThe molar concentration of PF4 tetramers is derived from the given monomer concentration, $C_{\\text{PF4,mono}} = 1.2 \\times 10^{-6} \\,\\mathrm{mol/L}$. Since PF4 is tetrameric ($\\phi \\approx 1$), the concentration of tetramers is one-fourth the concentration of monomers:\n$$C_{\\text{PF4,tetra}} = \\frac{C_{\\text{PF4,mono}}}{4} = \\frac{1.2 \\times 10^{-6} \\,\\mathrm{mol/L}}{4} = 3.0 \\times 10^{-7} \\,\\mathrm{mol/L}$$\nThe molar concentration of heparin must be derived from its activity dose.\nHeparin dose: $H = 0.5 \\,\\mathrm{IU/mL}$\nHeparin potency: $P = 180 \\,\\mathrm{IU/mg}$\nHeparin molecular weight: $M_{\\text{hep}} = 1.5 \\times 10^{4} \\,\\mathrm{g/mol}$\n\nFirst, convert the activity concentration ($H$) to mass concentration ($C_{\\text{hep,mass}}$) using potency ($P$):\n$$C_{\\text{hep,mass}} = \\frac{H}{P} = \\frac{0.5 \\,\\mathrm{IU/mL}}{180 \\,\\mathrm{IU/mg}} = \\frac{0.5}{180} \\,\\frac{\\mathrm{mg}}{\\mathrm{mL}}$$\nTo facilitate conversion to molarity, we express this in units of $\\mathrm{g/L}$:\n$$C_{\\text{hep,mass}} = \\frac{0.5}{180} \\,\\frac{\\mathrm{mg}}{\\mathrm{mL}} \\times \\frac{1000 \\,\\mathrm{mL}}{1 \\,\\mathrm{L}} \\times \\frac{1 \\,\\mathrm{g}}{1000 \\,\\mathrm{mg}} = \\frac{0.5}{180} \\,\\frac{\\mathrm{g}}{\\mathrm{L}}$$\nNow, convert mass concentration to molar concentration ($C_{\\text{hep}}$) using the molecular weight ($M_{\\text{hep}}$):\n$$C_{\\text{hep}} = \\frac{C_{\\text{hep,mass}}}{M_{\\text{hep}}} = \\frac{\\left( \\frac{0.5}{180} \\right) \\,\\mathrm{g/L}}{1.5 \\times 10^{4} \\,\\mathrm{g/mol}} = \\frac{0.5}{180 \\times 1.5 \\times 10^{4}} \\,\\mathrm{mol/L}$$\n$$C_{\\text{hep}} = \\frac{0.5}{2.7 \\times 10^{6}} \\,\\mathrm{mol/L} \\approx 1.85185... \\times 10^{-7} \\,\\mathrm{mol/L}$$\nThe actual molar ratio of PF4 tetramers to heparin chains in the mixture, $r_{\\text{mix}}$, is:\n$$r_{\\text{mix}} = \\frac{C_{\\text{PF4,tetra}}}{C_{\\text{hep}}} = \\frac{3.0 \\times 10^{-7} \\,\\mathrm{mol/L}}{\\frac{0.5}{2.7 \\times 10^{6}} \\,\\mathrm{mol/L}} = \\frac{3.0 \\times 10^{-7} \\times 2.7 \\times 10^{6}}{0.5} = \\frac{3.0 \\times 2.7}{0.5} = 6.0 \\times 2.7 = 16.2$$\nNow, we check if $r_{\\text{mix}}$ falls within the high-antigenicity window defined by $|Q| \\le \\alpha \\, z_{-}$ with $\\alpha = 0.1$. The residual net charge $Q$ for a complex formed at this ratio is:\n$$Q = r_{\\text{mix}} \\cdot z_{t} - z_{-} = (16.2)(12) - 80 = 194.4 - 80 = 114.4$$\nThe threshold for the high-antigenicity window is:\n$$\\alpha \\, z_{-} = 0.1 \\times 80 = 8$$\nWe compare the absolute value of the residual charge, $|Q| = |114.4| = 114.4$, to this threshold:\n$$114.4 > 8$$\nConclusion: The actual ratio in the assay, $r_{\\text{mix}} = 16.2$, is significantly higher than the optimal ratio $r^{\\ast} \\approx 6.667$. The resulting complexes are strongly positively charged, and the condition for high antigenicity is not met. The mixture is in a state of significant PF4 excess relative to the charge-neutral stoichiometry.\n\n**4. Explanation for reduced signal intensity away from $r^{\\ast}$**\n\nThe immunoassay signal is proportional to the concentration of stable, antibody-binding antigenic complexes formed. The formation of these complexes is governed by principles of polyelectrolyte complexation and the law of mass action.\n\nThe ideal antigenic complex in HIT is a large, aggregated, multivalent structure formed when PF4 (a polycation) and heparin (a polyanion) combine in a ratio, $r^{\\ast}$, that approaches electrostatic neutrality. At this stoichiometry, the repulsive forces between macromolecules are minimized, and attractive forces (electrostatic and others) dominate, leading to the coacervation or precipitation of large complexes. These large complexes provide a high density of epitopes for antibody binding, enabling efficient cross-linking of antibodies and producing a strong signal in an ELISA format.\n\nDeviations from the optimal ratio $r^{\\ast}$ disrupt this process:\n- **Case 1: Heparin Excess ($r < r^{\\ast}$)**: When heparin is in excess, the resulting PF4–heparin complexes are net-negative. Electrostatic repulsion between these negatively charged complexes prevents them from aggregating into larger structures. Instead, smaller, soluble complexes are formed. These smaller complexes are less efficient at binding and cross-linking antibodies, leading to a reduced immunoassay signal. This phenomenon is often termed the \"prozone effect\" in immunology.\n- **Case 2: PF4 Excess ($r > r^{\\ast}$)**: This corresponds to the situation calculated in part 3, where $r_{\\text{mix}} > r^{\\ast}$. When PF4 is in excess, the resulting complexes are net-positive. Similar to the heparin-excess case, electrostatic repulsion between these positively charged complexes inhibits their assembly into large, optimally antigenic aggregates. The system is dominated by smaller, soluble complexes where individual heparin chains may be 'coated' with an excess of PF4 tetramers. These species are also poor antigens, resulting in a low signal.\n\nFrom the perspective of mass action, the formation of the most antigenic complex, $C^{\\ast}$, can be represented by the equilibrium: $r^{\\ast} \\text{PF4}_{\\text{tetra}} + \\text{heparin} \\rightleftharpoons C^{\\ast}$. According to Le Châtelier's principle, the concentration of the product, $[C^{\\ast}]$, is maximized when the reactants are present in their stoichiometric ratio. When one reactant is in significant excess (either PF4 or heparin), the concentration of the limiting reactant determines the maximum possible concentration of complexes, and the formation of the specific, large aggregated structures ($C^{\\ast}$) is suppressed in favor of smaller, soluble, non-stoichiometric complexes. Therefore, any significant deviation from $r=r^{\\ast}$ leads to a lower concentration of the highly antigenic species and, consequently, a weaker immunoassay signal.", "answer": "$$\\boxed{6.667}$$", "id": "5224041"}, {"introduction": "The Serotonin Release Assay (SRA) is the gold-standard functional test for confirming HIT. This exercise places you in the role of a laboratory professional, tasking you with converting raw radioactivity counts from an SRA into a clinically meaningful \"release fraction\" [@problem_id:5224077]. You will learn to identify the characteristic HIT signature: strong platelet activation at low heparin concentrations that is suppressed at higher heparin levels, a key pattern for positive diagnosis.", "problem": "A functional assay for Heparin-Induced Thrombocytopenia (HIT) such as the Serotonin Release Assay (SRA) measures activation of donor platelets by patient immunoglobulin G (IgG) in the presence of heparin. Platelets are preloaded with radiolabeled serotonin, and upon activation they release serotonin into the supernatant, which is quantified as counts per minute (cpm). The total platelet serotonin content is measured after complete lysis (total cpm). By definition, the release fraction is the ratio of released serotonin to total serotonin, computed as the supernatant cpm divided by the total cpm for the same condition. A characteristic HIT pattern is high release at low heparin with suppression at high heparin toward baseline (no heparin).\n\nA laboratory performs an SRA using a single healthy donor platelet preparation with the following raw measurements:\n- Baseline (no heparin): supernatant $5720$ cpm; total (lysis) $52000$ cpm.\n- Low heparin: supernatant $23690$ cpm; total (lysis) $51500$ cpm.\n- High heparin: supernatant $6096$ cpm; total (lysis) $50800$ cpm.\n\nUsing only the definition of release fraction as described above, compute the release fraction for the low heparin condition. Then, based on the commonly observed HIT signature (elevated release at low heparin and suppression at high heparin toward baseline, with low-heparin release at least $0.20$), briefly interpret whether these data are qualitatively consistent with HIT-mediated platelet activation. Express your final numeric answer as a decimal fraction (for example, write $0.65$ for $65$ percent), and round your final numeric answer to three significant figures. Do not include a percent sign in your numeric answer.", "solution": "The problem requires the calculation of the release fraction for the low heparin condition and an interpretation of the results in the context of a Heparin-Induced Thrombocytopenia (HIT) assay. The problem is scientifically grounded, well-posed, and objective, and therefore is valid.\n\nFirst, we formalize the definition of the release fraction, which we denote as $R$. The release fraction is the ratio of the released serotonin, measured as supernatant counts per minute ($S_{cpm}$), to the total serotonin content, measured as total counts per minute ($T_{cpm}$) after platelet lysis.\n$$R = \\frac{S_{cpm}}{T_{cpm}}$$\n\nWe are given data for three conditions: baseline (no heparin), low heparin, and high heparin. We will calculate the release fraction for each condition using the provided data.\n\nFor the baseline condition:\nSupernatant cpm, $S_{base} = 5720$.\nTotal cpm, $T_{base} = 52000$.\nThe baseline release fraction, $R_{base}$, is:\n$$R_{base} = \\frac{5720}{52000} = 0.11$$\n\nFor the low heparin condition:\nSupernatant cpm, $S_{low} = 23690$.\nTotal cpm, $T_{low} = 51500$.\nThe low heparin release fraction, $R_{low}$, is:\n$$R_{low} = \\frac{23690}{51500} = 0.46$$\n\nFor the high heparin condition:\nSupernatant cpm, $S_{high} = 6096$.\nTotal cpm, $T_{high} = 50800$.\nThe high heparin release fraction, $R_{high}$, is:\n$$R_{high} = \\frac{6096}{50800} = 0.12$$\n\nThe second part of the problem asks for an interpretation of whether these data are qualitatively consistent with HIT-mediated platelet activation. A characteristic HIT signature is defined by three criteria:\n1.  Elevated release at low heparin strength.\n2.  Suppression of release at high heparin strength, toward the baseline level.\n3.  The low-heparin release fraction value must be at least $0.20$.\n\nWe evaluate our calculated release fractions against these criteria:\n1.  The release fraction at low heparin, $R_{low} = 0.46$, is substantially elevated compared to the baseline release fraction, $R_{base} = 0.11$. This criterion is met.\n2.  The release fraction at high heparin, $R_{high} = 0.12$, is markedly suppressed from the peak value of $0.46$ and is very close to the baseline value of $0.11$. This criterion is met.\n3.  The low-heparin release fraction, $R_{low} = 0.46$, is greater than the specified threshold of $0.20$. This criterion is met.\n\nSince all three criteria are satisfied, the data are qualitatively consistent with a positive result for HIT-mediated platelet activation.\n\nThe problem asks for the final numeric answer to be the release fraction for the low heparin condition, rounded to three significant figures. The calculated value is exactly $0.46$. To express this with three significant figures, we include a trailing zero, which indicates the precision of the result.\n$$R_{low} = 0.460$$", "answer": "$$\n\\boxed{0.460}\n$$", "id": "5224077"}, {"introduction": "A definitive diagnosis is rarely based on a single test result; rather, it emerges from a synthesis of evidence. This problem simulates a common diagnostic pathway in which a screening immunoassay is followed by a more specific functional assay [@problem_id:5224040]. Applying the principles of Bayesian inference, you will quantitatively update the probability of a patient having HIT as new test results become available, demonstrating how sequential testing refines diagnostic certainty from an initial suspicion to a conclusive finding.", "problem": "A patient receiving unfractionated heparin develops thrombocytopenia with an intermediate clinical suspicion for Heparin-Induced Thrombocytopenia (HIT) by the 4Ts score. Assume the pre-test probability of true HIT is $0.20$. In a stepwise diagnostic algorithm, the patient first undergoes a Platelet Factor 4 (PF4)/heparin Enzyme-Linked Immunosorbent Assay (ELISA) immunoassay, followed by a functional Serotonin Release Assay (SRA). The PF4/heparin ELISA has sensitivity $0.98$ and specificity $0.85$. The SRA has sensitivity $0.95$ and specificity $0.99$. Both test results are positive.\n\nAssume that, conditional on the true disease state (HIT present vs. absent), the test outcomes are independent of each other. Using first principles in probability to reason about diagnostic testing in laboratory diagnostics, compute the updated posterior probability that the patient has true HIT after observing the sequential positive results. Round your final answer to four significant figures and express it as a decimal.", "solution": "The problem is a valid application of Bayesian inference to a clinical diagnostic scenario. All necessary information is provided, the parameters are scientifically reasonable for the context of Heparin-Induced Thrombocytopenia (HIT) diagnostics, and the question is well-posed. We will proceed with a formal solution.\n\nLet us define the following events:\n- $H$: The event that the patient has true HIT.\n- $H^c$: The event that the patient does not have HIT.\n- $E^+$: The event that the Platelet Factor 4 (PF4)/heparin ELISA test is positive.\n- $S^+$: The event that the Serotonin Release Assay (SRA) is positive.\n\nFrom the problem statement, we are given the following probabilities:\n- The pre-test probability of HIT: $P(H) = 0.20$.\n- The probability of not having HIT is therefore $P(H^c) = 1 - P(H) = 1 - 0.20 = 0.80$.\n\nFor the ELISA test:\n- Sensitivity: $P(E^+ | H) = 0.98$.\n- Specificity: $P(E^- | H^c) = 0.85$, where $E^-$ is a negative result. The probability of a positive result in a non-diseased patient (a false positive) is $P(E^+ | H^c) = 1 - P(E^- | H^c) = 1 - 0.85 = 0.15$.\n\nFor the SRA test:\n- Sensitivity: $P(S^+ | H) = 0.95$.\n- Specificity: $P(S^- | H^c) = 0.99$, where $S^-$ is a negative result. The probability of a false positive is $P(S^+ | H^c) = 1 - P(S^- | H^c) = 1 - 0.99 = 0.01$.\n\nThe problem states that both tests are positive. We are asked to compute the posterior probability of HIT given this combined evidence, which is denoted as $P(H | E^+ \\cap S^+)$. We will use Bayes' theorem for this calculation:\n$$P(H | E^+ \\cap S^+) = \\frac{P(E^+ \\cap S^+ | H) P(H)}{P(E^+ \\cap S^+)}$$\n\nThe term $P(E^+ \\cap S^+)$ in the denominator can be expanded using the law of total probability:\n$$P(E^+ \\cap S^+) = P(E^+ \\cap S^+ | H) P(H) + P(E^+ \\cap S^+ | H^c) P(H^c)$$\n\nThe problem states a critical assumption: a patient's test results are independent, conditional on their true disease state. This simplifies the joint conditional probabilities:\n- $P(E^+ \\cap S^+ | H) = P(E^+ | H) P(S^+ | H)$\n- $P(E^+ \\cap S^+ | H^c) = P(E^+ | H^c) P(S^+ | H^c)$\n\nSubstituting these expressions back into the formula for Bayes' theorem, we get:\n$$P(H | E^+ \\cap S^+) = \\frac{P(E^+ | H) P(S^+ | H) P(H)}{P(E^+ | H) P(S^+ | H) P(H) + P(E^+ | H^c) P(S^+ | H^c) P(H^c)}$$\n\nNow, we substitute the numerical values into this expression.\nThe numerator is the probability of having HIT and observing two positive tests:\n$$P(\\text{Numerator}) = P(E^+ | H) P(S^+ | H) P(H) = (0.98)(0.95)(0.20)$$\n$$P(\\text{Numerator}) = (0.931)(0.20) = 0.1862$$\n\nThe denominator is the total probability of observing two positive tests, across both HIT and non-HIT populations. It consists of two terms:\nThe first term is identical to the numerator:\n$$P(E^+ \\cap S^+ | H) P(H) = 0.1862$$\nThe second term is the probability of not having HIT and observing two positive tests (two false positives):\n$$P(E^+ \\cap S^+ | H^c) P(H^c) = P(E^+ | H^c) P(S^+ | H^c) P(H^c) = (0.15)(0.01)(0.80)$$\n$$P(\\text{second term}) = (0.0015)(0.80) = 0.0012$$\n\nThe total probability in the denominator is the sum of these two terms:\n$$P(E^+ \\cap S^+) = 0.1862 + 0.0012 = 0.1874$$\n\nFinally, we compute the posterior probability:\n$$P(H | E^+ \\cap S^+) = \\frac{0.1862}{0.1874} \\approx 0.99359658...$$\n\nThe problem requires the answer to be rounded to four significant figures.\n$$P(H | E^+ \\cap S^+) \\approx 0.9936$$\n\nThus, after observing positive results from both the highly sensitive ELISA and the highly specific SRA, the probability that the patient has HIT increases from the initial pre-test probability of $20\\%$ to approximately $99.36\\%$.", "answer": "$$\\boxed{0.9936}$$", "id": "5224040"}]}